- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No studies have been conducted on pharmacokinetic parameters in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Prophylaxis and treatment of cardiomyopathy in boys with Duchenne Muscular Dystrophy | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Perindopril base:
- creatinine clearance 30-50 ml/min: no dose adjustments required.
- creatinine clearance 10-30 ml/min: max. 1.7 mg/day in 1 dose, every 2 days or according to effect up to the highest possible tolerated dose (protective effect on renal function)
This equals:
-
- ‘tertbutylamine’ (= ‘erbumine’): max. 2 mg/day, in 1 dose, every 2 days or according to effect up to the highest possible tolerated dose (protective effect on renal function)
- ‘arginine’: max. 2.5 mg/day in 1 dose, every 2 days or up to the highest tolerated dose according to effect (protective effect on renal function).
- ‘tosilate’: max. 2.5 mg/day in 1 dose, every 2 days or up to the highest tolerated dose according to effect (protective effect on renal function).
Clinical consequences
ACE inhibitors decrease intraglomerular filtration pressure and reduce proteinuria. As a result, they probably have a long-term protective effect on kidney function. For this reason, the highest possible dose is also given according to tolerance.
Creatinine and potassium concentrations should be monitored within 2 weeks of starting treatment and then at least once a year, depending on the patient's clinical condition
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
No specific side effects in children have been described in the literature.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Different products may contain different salts of perindopril.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| ACE inhibitors, plain | ||
|---|---|---|
| C09AA07 | ||
| C09AA01 | ||
| C09AA02 | ||
| C09AA03 | ||
| C09AA05 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Bourke JP, et al, Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy., Cochrane Database Syst Rev, 2018, 10(10), Cd009068.
- Bourke JP, et al., Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial., Neurol Clin Pract., 2021, 11(5), e661-e8
- Duboc D, et al. 2005;, Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy., J Am Coll Cardiol., 2005, 45(6), 855-7
- Duboc D, et al., Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up., Am Heart J, 2007, 154(3), 596-602
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
